Inhibitors of immune-checkpoint proteins, such as PD1, PD-L1, VISTA, Tim3 and Lag3, have indicated broad and diverse opportunities to increase antitumor immunity by enhancing T cell activity with the potential to produce durable clinical responses. To meet these needs, we have developed stable cell line products expressing the most popular immune checkpoints to accelerate your immunotherapy discovery and clinical translation. All these stable cells are developed for screening high affinity antibodies or compounds against immune checkpoint proteins.
Stable Cell Line Catalog Products for Immune Checkpoint Drug Discovery are generated with advanced technologies of lentiviral transduction and antibiotic selection system, carefully screened for single clone with high performance, and fully quality assured.
In this webinar, you will learn:
- Workflow of generating Stable Cell Line Catalog Product for immune oncology drug discovery.
- Technologies applied by GenScript to ensure high quality and excellent performance.
- How are these stable cell lines utilized as indispensable tools during immune oncology drug discovery.
- What are the key features to make the Stable Cell Line Catalog Products the ultimate cellular tools for drug discovery.